Hindsén 2006 (P).

Methods	DESIGN Between‐patient Participant delivery ALLOCATION Random Method of randomisation: not stated Concealment: unclear BLINDING Double‐blind (participant/investigator) WITHDRAWAL/DROPOUT Not described
Participants	N: 360 Treatment duration: 2 or 6 wks; FU: 6 or 10 wks LF: NR BC: not demonstrated Age: NR Gender (per cent men): NR Severity: NR INCLUSION CRITERIA People with moderately severe plaque psoriasis on elbows, knees, or both EXCLUSION CRITERIA Not stated
Interventions	Calcipotriol ointment 50 mcg/g, BD (no occlusion) for 6 wks (C) Calcipotriol ointment 50 mcg/g plus occlusion, once/week for 2 wks (CO) Placebo ointment plus occlusion, once/week for 2 wks (P)
Outcomes	Total Sign Score (redness, thickness, scaliness) (TSS): 0 to 24
Notes	Leo Pharma, Ballerup, sponsored the trial. It was unclear how participants were blinded to treatment options where 2/3 involved occlusion. The sponsor supplied unpublished data.
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment (selection bias)	Unclear risk	The trial reported insufficient details.
Blinding (performance bias and detection bias) All outcomes	Unclear risk	The trial was reported to be double‐blind (participant/investigator), but it was unclear how they blinded participants to treatment options where 2/3 involved occlusion.
Randomisation method reported	Unclear risk	The trial did not report this.
Loss to follow up	Unclear risk	The trial did not report this.
Baseline assessments	Unclear risk	The trial did not report these.
Baseline comparability demonstrated	Unclear risk	This was not demonstrated.